HTGF | High-Tech Gruenderfonds
High-Tech Gründerfonds Management GmbH is a venture capital firm based in Bonn, Germany, specializing in early-stage investments in high-tech startups. Established in 2005, the firm focuses on technology-driven companies across various sectors, including information and communication technology, life sciences, healthcare, automation, and cleantech. HTGF typically invests in companies that have been operational for no more than one year, aiming to contribute up to €0.6 million in initial funding and up to €3 million in follow-on financing. The firm seeks a minority stake, generally around 15%, and provides a subordinated loan convertible into equity, with deferred interest for up to four years to support liquidity. With a total investment volume of approximately €895.5 million across three funds, HTGF has successfully supported over 500 startups and attracted more than €2 billion in follow-on investments from external sources. The firm's investors include notable public and private entities, underscoring its role as a key player in fostering innovation and growth within the German startup ecosystem.
Top Sectors
https://crunchbase.com/organization/***
https://linkedin.com/company/***
https://signal.nfx.com/firms/***
Past deals in Hospital
Hema.to
Seed Round in 2025
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Avelios Medical
Series A in 2025
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Lindis Blood Care
Venture Round in 2024
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Hema.to
Seed Round in 2023
Hema.to specializes in AI-powered blood cancer detection software. It automates the analysis of flow cytometry data, enhancing lab efficiency and accuracy.
Lindis Blood Care
Venture Round in 2022
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
Avelios Medical
Seed Round in 2021
Avelios Medical operates a modular clinic platform designed to enhance patient care by digitizing and optimizing clinic processes. The platform provides comprehensive support for healthcare staff, streamlining their daily tasks and fostering the integration of advanced technologies. By incorporating innovations such as artificial intelligence, big data, telemedicine, patient applications, and wearables, Avelios Medical aims to fundamentally transform healthcare delivery and research. This approach not only automates various operational processes but also enhances the overall efficiency and effectiveness of hospitals and clinics.
Lindis Blood Care
Venture Round in 2019
Lindis Blood Care is focused on improving the outcomes of cancer surgeries through the development of an innovative medical device that removes cancer cells from salvaged blood. This technology facilitates the possibility of self-blood administration, allowing cancer patients to receive autologous blood transfusions during their procedures. By enabling the safe use of blood collected during surgery, Lindis Blood Care aims to enhance the recovery process and overall well-being of patients undergoing cancer treatment.
GWA Hygiene
Venture Round in 2018
GWA Hygiene GmbH is a German company based in Stralsund, established in 2015, that specializes in the development of hygiene monitoring solutions for healthcare settings. The company manufactures sensors designed to monitor hand hygiene standards among hospital personnel and is expanding its offerings to include surface disinfection monitoring. GWA Hygiene's technology integrates with disinfectant and soap dispensers, equipping them with sensors to capture data on disinfection practices. This data can be displayed on monitors and is accessible via a software application that analyzes disinfection rates across different wards and professional groups. Users have the option to store data on their own servers or utilize GWA Hygiene's secure cloud storage. Additionally, the company's software toolbox aids in logistical tasks related to hygiene management, such as managing dispenser refills and device maintenance.
Dolosys
Venture Round in 2013
Dolosys GmbH is a Berlin-based medical technology company specializing in the development and production of devices for the objective measurement of pain and pain management. The company focuses on creating innovative equipment that assists healthcare providers in monitoring and controlling pain, particularly for sedated intensive care patients and individuals suffering from chronic pain. By optimizing pain therapy, Dolosys aims to enhance pain management alternatives available to healthcare organizations, ultimately improving patient care and outcomes.
Seiratherm
Venture Round in 2012
Seiratherm is a privately held medical technology company located in Herzogenaurach, Germany, specializing in fluid and body-temperature management devices. The company's innovative devices are designed to quickly and safely regulate the core body temperature of critically ill or surgical patients, targeting pre-set treatment goals. By effectively managing body temperature, Seiratherm's devices help lower metabolic rates, which can reduce neurological damage and enhance the treatment of conditions such as hypothermia, normothermia, and hyperthermia. This approach enables healthcare professionals to deliver more efficient and effective care to patients in critical situations.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.